Insys Therapeutics decreases range, now plans to raise $36 million

By
A A A

Insys Therapeutics, which markets opioid and synthetic marijuana drugs for cancer pain and CINV, lowered the proposed deal size for its upcoming IPO on Thursday. The Phoenix, AZ-based company now plans to raise $36 million by offering 4 million shares at a price range of $8 to $10. The company had previously filed to offer 4 million shares at a range of $16 to $18. At the midpoint of the revised range, Insys Therapeutics will raise 47% fewer proceeds than previously anticipated.

Insys Therapeutics, which was founded in 1990 and booked $15 million in sales for the year ended December 31, 2012, plans to list on the NASDAQ under the symbol INSY. Wells Fargo Securities and JMP Securities are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: INSY

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

36,586,989
  • $41.35 ▼ 2.29%
33,435,019
  • $42.20 ▼ 10.86%
31,919,424
  • $9.72 ▼ 8.30%
30,045,396
  • $26.49 ▼ 1.41%
29,014,873
  • $8.05 ▼ 8%
27,308,018
  • $14.66 ▼ 8.32%
23,704,242
  • $118.93 ▼ 0.06%
23,514,654
  • $17.04 ▼ 0.41%
As of 11/28/2014, 01:06 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com